The results of this study go beyond the limitation of HCPs’ self-reported performance to suggest that patient simulation CME is reflective of real-world practice behavior, as there was concordance (within the same phase I time frame) in decision-making between the percentage of clinicians who selected GLP-1 RAs in the CME simulation prior to feedback (178/435, 41%) and the entire population of clinicians using GLP-1 RAs for patients with T2D in the real world (394,133/947,437, 40.6%) prior to the intervention. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.